New Approaches to the Management of Gram-Negative Resistant Infections

In this Webcast of a live workshop, expert faculty review best practices in managing multidrug-resistant Gram-negative bacterial infections, with a focus on recently approved and emerging investigational treatment options.
Keith S. Kaye, MD, MPH
Program Director
Jason Pogue Headshot
Jason M. Pogue, PharmD
Michael Satlin Headshot
Michael Satlin, MD
Released: November 8, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the epidemiology and changing patterns of multidrug resistance of Gram-negative bacteria to include local trends and the significance of this information in clinical practice
  • Explore key clinical trial data on new and emerging therapeutic options against multidrug-resistant Gram-negative bacteria, with attention to safety, efficacy, and adverse event profiles of newer agents vs those of established agents of the same class
  • Discuss individualized management approaches to the treatment of multidrug-resistant Gram-negative infections with a focus on next-generation antimicrobial agents and their potential utility for reducing resistance and improving patient-specific administration and dosing considerations

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Keith S. Kaye, MD, MPH

Professor
Division of Infectious Diseases
Department of Internal Medicine
University of Michigan Medical School
University of Michigan Health System
Ann Arbor, Michigan

Keith S. Kaye, MD, MPH, has disclosed that he has received consulting fees from Achaogen, Melinta, Merck, Nabriva, Paratek, Shionogi, The Medicines Company, and Xellia.

Faculty

Jason M. Pogue, PharmD

Clinical Assistant Professor of Medicine
Wayne State University School of Medicine
Clinical Pharmacist, Infectious Diseases
Department of Pharmacy
Sinai-Grace Hospital
Detroit Medical Center
Detroit, Michigan

Jason M. Pogue, PharmD, has disclosed that he has received consulting fees from Achaogen, Allergan, Melinta, Merck, Shionogi, Tetraphase, and The Medicines Company and fees for non-CME/CE services from Allergan, Melinta, and Merck.
Michael Satlin, MD

Associate Professor
Division of Infectious Diseases
Department of Internal Medicine
Weill Cornell Medicine
New York, New York

Michael Satlin, MD, has disclosed that he has received consulting fees from Achaogen and funds for research support from Allergan and Merck.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Associate Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and other healthcare providers who care for patients with multidrug-resistant Gram-negative infections.

Goal

The goal of this activity is to improve participants’ knowledge and competence in applying current and emerging antibacterials in the management of patients with resistant Gram-negative infections.

Program Medium

This program has been made available online.

Related Content

Watch this CME/CPE video module from CCO to learn systems-based strategies for expanding the role of pharmacists in HCV and HIV management

John Faragon, PharmD, BCPS, AAHIVP
Program Director
Michelle T. Martin, PharmD, FCCP, BCPS, BCACP Rupa Patel, MD, MPH, DTM&H
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 22, 2019 Expiration: May 21, 2020

In this ClinicalThought commentary from CCO, Dr. Michelle Martin provides insights on how pharmacists can lead HCV screening efforts nationwide

Michelle T. Martin, PharmD, FCCP, BCPS, BCACP Released: May 21, 2019

Commentary from Jennifer Cocohoba, PharmD, on the potential for pharmacy-based PrEP provision to increase PrEP uptake and contribute to HIV prevention.

Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Released: May 14, 2019

CME-certified video from CCO on emerging therapies with novel MoAs for invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expiration: April 23, 2020
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?